Safety of prophylactic intracameral moxifloxacin use in cataract surgery
Related Experiment Video
Updated: May 25, 2026
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
Bengu Ekinci Koktekir1, Bekir Sitki Aslan
1Selcuklu Faculty of Medicine, Selcuk University, Konya, Turkey. benguekinci@hotmail.com
Purpose:
To evaluate posterior and anterior segment safety of an intracameral injection of moxifloxacin as prophylaxis for endophthalmitis in cataract surgery.
Methods:
In this study, 60 eyes of 60 patients were included. In the first group, only 5% povidine iodine drop was administrated to 30 patients at the end of the surgery, while 30 patients were treated with intracameral moxifloxacin (250 μg/0.050 mL) additionally in the second group. Visual acuity, intraocular pressure, corneal pachymetry, corneal clarity, and edema and retinal thickness were evaluated preoperatively and for day 3 postoperatively for each group and were compared.
Results:
Mean preoperative visual acuity was 0.7 ± 0.9 LogMAR in both groups 1 and 2, while mean postoperative visual acuity was 0.05 ± 1.00 LogMAR in both groups. Preoperative and postoperative intraocular pressure averaged 13.2 ± 2.0 and 13.2 ± 2.1 mmHg, respectively, in the first group, while preoperative and postoperative intraocular pressure was 14.9 ± 2.1 and 14.3 ± 2.0, respectively, in the second group. Preoperative and postoperative visual acuity changes and intraocular pressure changes were not significantly different between 2 groups. There was no single case of corneal edema. In the first group, preoperative pachymetry was 523 ± 44 and postoperative pachmetry was 536 ± 45 μm, while in the second group preoperative pachymetry was 527 ± 43 and postoperative pachymetry was 543 ± 42 μm. Preoperative and postoperative pachymetry changes were not significantly different between 2 groups. Mean preoperative macular thickness in the first group was 188 ± 7.73 μm, while it was measured as 189 ± 7.75 μm postoperatively. In the second group, mean preoperative macular thickness was 188 ± 8.89 μm, while it was 189 ± 9.61 μm postoperatively. Preoperative and postoperative optical coherence tomography (OCT) measure changes were not significantly different between the 2 groups. No study-related adverse events were noted.
Conclusion:
There was no increased safety risk associated with a 250 μm/0.050 mL intracameral injection of moxifloxacin, which appears to be safe in the prophylaxis of endophthalmitis after cataract surgery.
Insights
Intracameral moxifloxacin injection is safe for preventing endophthalmitis after cataract surgery. This study found no increased safety risks in patients receiving moxifloxacin compared to standard care.
Area of Science:
- Ophthalmology
- Surgical Infections
- Pharmacology
Background:
- Endophthalmitis is a serious complication following cataract surgery.
- Prophylaxis is crucial to minimize infection risk.
- Antibiotic agents are commonly used for prophylaxis.
Purpose of the Study:
- To assess the safety of intracameral moxifloxacin as an endophthalmitis prophylaxis.
- To evaluate potential adverse effects on the anterior and posterior segments of the eye.
Main Methods:
- A comparative study involving 60 patients undergoing cataract surgery.
- Group 1 received standard 5% povidone-iodine drops.
- Group 2 received intracameral moxifloxacin (250 μg/0.050 mL) in addition to povidone-iodine.
Main Results:
- No significant differences in visual acuity, intraocular pressure, or corneal pachymetry between groups.
- No cases of corneal edema or significant changes in macular thickness were observed.
- No study-related adverse events were reported for the moxifloxacin group.
Conclusions:
- Intracameral moxifloxacin at a dose of 250 μg/0.050 mL demonstrates a favorable safety profile.
- The use of intracameral moxifloxacin is safe for endophthalmitis prophylaxis in cataract surgery.
- No increased safety risks were associated with this prophylactic regimen.
Related Concept Videos
01:28Angle Closure Glaucoma: Treatment
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:23Ophthalmic Drug Delivery Systems